Efficacy and safety of fluorouracil + epirubicin + cyclophosphamide (FEC) versus FEC + docetaxel in patients with high-risk node-negative breast cancer.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Jan 2013

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

08 Dec 2012 Results presented at the 35th Annual San Antonio Breast Cancer Symposium.
08 Dec 2012 The primary endpoint 'Disease-free-survival-rate' has not been met, as reported in SABCS abstract.
05 Nov 2010 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com